PT - JOURNAL ARTICLE AU - Bhaijee, Feriyl AU - Jordan, Brenda AU - Pepper, Dominique J. AU - Leacock, Rodney AU - Rock, William A. TI - Venous Thrombosis with Both Heterozygous Factor V Leiden (R507Q) and Factor II (G20210A) Mutations AID - 10.29074/ascls.25.4.199 DP - 2012 Oct 01 TA - American Society for Clinical Laboratory Science PG - 199--205 VI - 25 IP - 4 4099 - http://hwmaint.clsjournal.ascls.org/content/25/4/199.short 4100 - http://hwmaint.clsjournal.ascls.org/content/25/4/199.full SO - Clin Lab Sci2012 Oct 01; 25 AB - Both hereditary and acquired factors increase the risk of venous thromboembolism, thus the clinical management of affected patients involves evaluation of genetic factors that predispose to hypercoagulability. Factor V Leiden (R507Q) and factor II (prothrombin) mutation (G20210A) are the two most common inherited hypercoagulability disorders among populations of European origin. Both factor V Leiden and factor II mutation (G20210A) represent gain-of-function mutations: factor V Leiden causes resistance to activated protein C, and factor II mutation (G20210A) results in higher levels of plasma prothrombin. Herein, we present an uncommon case of combined factor V Leiden mutation (R507Q) and factor II mutation (G20210A), and discuss the prevalence and features of each entity, as well as their role in the clinical management of affected patients.ABBREVIATIONSEDTA–ethylenediaminetetraacetic acid, VTE–venous thromboembolism, APC–activated protein C,